Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Clinical evidence

NIH phase 1-2a trial

68 evidence topics · 9 sources

Objective
Location and study date
Registry dates, enrollment, and single study location
Study design
Eligibility criteria
Exclusion criteria: severe or asymptomatic disease, prior cyclodextrin, and conditions affecting lumbar puncture or audiology

“Severe manifestations of NPC1 that would interfere with the patient's ability to comply with the requirements of this protocol.” (opens the source at this quote in a new tab)

“Neurologically asymptomatic patients.” (opens the source at this quote in a new tab)

“Patients who have received any form of cyclodextrin in an attempt to treat NPC1. Treatment with another drug preparation for another medical indication that contains cyclodextrin as an excipient, will not exclude a patient.” (opens the source at this quote in a new tab)

“Spinal deformity that would impact the ability to perform a lumbar puncture” (opens the source at this quote in a new tab)

“Contraindication for anesthesia.” (opens the source at this quote in a new tab)

“Patients unable to complete a behavioral audiologic evaluation including pure-tone threshold assessment (500 Hz to 8000 Hz) to monitor for ototoxicity and for whom otoacoustic emissions (OAEs) cannot be reliably obtained at baseline.” (opens the source at this quote in a new tab)

“Patients with ongoing seizures, that are not stable in frequency, type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using plasma 24(S)-Hydroxycholesterol area under the curve as the primary endpoint
Registered primary and secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment of 14 participants
FieldQuoted record
Enrollment (actual)“14”
Phase“Phase 1”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary: design limitations of the NIH phase 1-2a trial
  • Control and external comparison: the trial was a non-randomized, open-label, single-center dose escalation study. The authors state that it “relies on a historical comparison group, and is not a randomized, placebo-controlled trial.” Efficacy compared NSS progression in the 14 NIH participants with a historical cohort of 21 participants from a natural history study, selected for two or more assessments within 25 months and an age of 4 to 24 years. Natural history participants were on average younger and had lower NSS at baseline (mean total NSS 14.5 ± 9.7 versus 19.3 ± 7.5), differences the authors report as not significant.
  • Analysis: the clinical efficacy data come from an ad-hoc analysis using a post hoc mixed model repeated measures approach. No formal sample size calculation was made, confidence intervals were not estimated given the small sample size, and the responder analysis used Fisher's exact test with a nominal p-value of 0.05.
  • Dose escalation: the authors state that the dose escalation design limits the ability to establish dose-response correlations. The publication describes monthly doses of 50 to 1200 mg in the 14 NIH participants and every-two-week dosing in three additional participants at Rush University Medical Center; the prescribing information describes doses of 200 to 1,200 mg once monthly, regimens it does not recommend.
  • Unequal follow-up and measurement: NSS data for three participants (CDA102, CDA113, and CDA114) were obtained at 12 months and for the others at 18 or 19 months. Behavioral audiograms could be obtained for 12 of 14 participants.
  • Concomitant miglustat: 12 (86%) treated and 16 (76%) natural history participants used miglustat. In the 36-month neuropsychological analysis, 11 of 14 participants took miglustat at baseline and throughout, and the small number not taking it prevented assessment of its confounding effect.
  • Neuropsychological follow-up: the analysis had no comparison or historical control group, was descriptive because the study was not designed to target neuropsychological efficacy, had no a priori power calculation, and had a sample below the n ≈ 30 suggested for the standard errors of the fixed effect. Fewer than 10 WRAML observations were available at most timepoints.
  • Confirmation: the authors state that data from a randomized, sham-controlled phase 2b/3 study would be needed to confirm the results.